Abstract 535P
Background
Glioblastoma (GBM) is the most common malignant primary brain tumor in adults. It remains a relatively rare disease with an incidence of 3/100.000 in France, and an age-related peak in incidence at 70 years of age, which corresponds to the age limit inclusion criteria of the Stupp Trial on 2005, cornerstone of the GBM strategy. Therefore, treatment of GBM in elderly patients is not standardized and depends on several clinical and biological factors. The aim of this study is to compare survival outcome of elderly patients with glioblastoma treated with standard radiotherapy (SRT) versus hypofractionated radiotherapy (HRT) versus no radiotherapy (RT), with or without Temozolomide.
Methods
A single-center retrospective case series analysis was conducted, including newly diagnosed GB patients older than 70 from January 2010 to December 2021. The Log-Rank test was used to compare the PFS and OS of patients treated with SRT versus HRT versus no RT. Furthermore, a Cox regression analysis was performed to identify risk factors associated with OS. Statistical significance was considered when p<0.05.
Results
A total of 304 patients were included with a median age of 74.36 years [71.63, 78.62], among whom, 142 were women. Most patients had a performans status of 0 or 1. Median OS was 11.4 months [95% CI 10.4 – 12.3] while median PFS was 8.1 months [95% CI 7.4 – 9.1]. Overall, 231 patients (76%) were treated with RT, 94 (30.9%) with SRT, 129 (42.4%) with HRT and 73 (24%) did not receive RT. On univariate analysis, the SRT group showed a better OS compared to the HRT and no RT groups (23.1 months, 11.1 months and 4.7 months, respectively, p<0.01). Same trend was observed for median PFS (SRT 13.6 months, 8.08 months and 3.7 months respectively, p<0.05).
Conclusions
While previous randomized trials showed a benefit or non-inferiority of HRT over SRT in elderly glioblastoma patients, this large retrospective “real-life” cohort shows on the contrary a benefit in terms of OS of the standard normo fractionated RT regimen. Standard treatment should not always be degraded in elderly patient, and a proportion of them may still benefit from standard RT if their clinical status allows it.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut Gustave Roussy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
561P - Risk of colorectal cancer and premalignant lesions after kidney transplantation
Presenter: Koen Zwart
Session: Poster session 10
562P - Quantifying the effect of colonoscopy and polypectomy rates in stage shift of colorectal cancer and reduced need for adjuvant chemotherapy
Presenter: Mina Sarofim
Session: Poster session 10
563P - The impact of participation in colorectal cancer screening: A population-based results from Lithuania
Presenter: Tomas Poskus
Session: Poster session 10
564P - A large-scale real-world study for colorectal cancer screening
Presenter: Song LIU
Session: Poster session 10
565P - Real-world data of early-onset colon cancer (early-onset CC) from the AIO colopredict plus (CPP) registry: Clinical and molecular characteristics, treatment and outcome
Presenter: Doreen Gisder
Session: Poster session 10
566P - Long-term survivorship outcomes of adolescents and young adults (AYA) with cancer of the lower gastrointestinal tract
Presenter: Winette Van Der Graaf
Session: Poster session 10
567P - Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients: Results from the PETACC 8 study
Presenter: Elisabeth Bergen
Session: Poster session 10
568P - Single cell AI-based detection of DNA mismatch repair deficiency in 1,988 colorectal cancers reveals prognostic and predictive value in the SCOT trial
Presenter: Faiz Jabbar
Session: Poster session 10
569P - Artificial intelligence for detection of mismatch repair deficiency in colon carcinomas (alliance)
Presenter: Frank Sinicrope
Session: Poster session 10
570P - Subclasses of microsatellite-instability colorectal cancer with unique molecular features and immune cell infiltration patterns
Presenter: Kui Wu
Session: Poster session 10